as 03-28-2025 4:00pm EST
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
Founded: | 1999 | Country: | United States |
Employees: | N/A | City: | NEW YORK |
Market Cap: | 1.1B | IPO Year: | N/A |
Target Price: | $44.10 | AVG Volume (30 days): | 1.6M |
Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.73 | EPS Growth: | N/A |
52 Week Low/High: | $7.48 - $26.99 | Next Earning Date: | 05-05-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
RCKT Breaking Stock News: Dive into RCKT Ticker-Specific Updates for Smart Investing
Insider Monkey
3 days ago
MT Newswires
17 days ago
Insider Monkey
24 days ago
Simply Wall St.
a month ago
Zacks
a month ago
Associated Press Finance
a month ago
Business Wire
a month ago
Zacks
2 months ago
The information presented on this page, "RCKT Rocket Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.